Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,308.13 +4.86 (+0.09%) Dow
39,806.77 -196.82 (-0.49%) Nasdaq
16,794.88 +108.91 (+0.65%) Bitcoin USD
71,152.82 +4,086.61 (+6.09%) CMC Crypto 200
1,545.82 +57.28 (+3.85%)
SNY May 2024 47.500 put
| Previous close | 0.0500 |
| Open | 0.3100 |
| Bid | 0.0000 |
| Ask | 0.2000 |
| Strike | 47.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3100 - 0.3100 |
| Contract range | N/A |
| Volume | |
| Open interest | 245 |
GlobeNewswirePress Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind w
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares - April 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
- GlobeNewswire
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targ
